A

fter months of controversy, the Colombian government has unilaterally lowered the price of a Novartis cancer drug by 44 percent, the latest step in a closely watched and particularly heated battle over access to medicines and intellectual property rights.

The move, which had been expected, comes after Colombian Health Minister Alejandro Gaviria issued a “declaration of public interest.” This allows the government to take various steps to reduce the price of a medicine, and Gaviria argued the price cut is justified because the cost for Gleevec is out of reach for some citizens.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories